{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:13:32Z","timestamp":1770459212434,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to evaluate the effects of Sacubitril\/Valsartan (S\/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling patients with HFrEF undergoing treatment with S\/V. The primary outcome was the composite of cardiac death and HF rehospitalization at 12 months follow-up; secondary outcomes were all-cause death, cardiac death and the occurrence of rehospitalization for worsening HF. The clinical outcome was compared with a retrospective cohort of 90 HFrEF patients treated with standard medical therapy. The study included 90 patients (66.1\u2009\u00b1\u200911.7 years) treated with S\/V. The adjusted regression analysis showed a significantly lower risk for the primary outcome (HR:0.31; 95%CI, 0.11\u20130.83; p\u2009=\u20090.019) and for HF rehospitalization (HR:0.27; 95%CI, 0.08\u20130.94; p\u2009=\u20090.039) in S\/V patients as compared to the control group. A significant improvement in NYHA class, left ventricular ejection fraction, left ventricular end systolic volume and systolic pulmonary arterial pressure was observed up to 6 months. S\/V did not affect negatively renal function and was associated with a significantly lower dose of furosemide dose prescribed at 6- and 12-month follow-up. In this study, S\/V reduced the risk of HF rehospitalization and cardiac death at 1 year in patients with HFrEF. S\/V improved NYHA class, echocardiographic parameters and need of furosemide, and preserved renal function.<\/jats:p>","DOI":"10.1038\/s41598-020-63801-2","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T10:03:19Z","timestamp":1587376999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical and echocardiographic benefit of Sacubitril\/Valsartan in a real-world population with HF with reduced ejection fraction"],"prefix":"10.1038","volume":"10","author":[{"given":"Maria Vincenza","family":"Polito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Silverio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Rispoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Vitulano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica D\u2019","family":"Auria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Loria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gigantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Bonadies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Citro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albino","family":"Carrizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"63801_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","volume":"119","author":"PS Jhund","year":"2009","unstructured":"Jhund, P. S. et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 119, 515\u2013523 (2009).","journal-title":"Circulation."},{"key":"63801_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.109.909614","volume":"121","author":"MR Zile","year":"2010","unstructured":"Zile, M. R. et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 121, 1393\u20131405 (2010).","journal-title":"Circulation."},{"issue":"4","key":"63801_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.507","volume":"18","author":"J Butler","year":"2016","unstructured":"Butler, J., Gheorghiade, M. & Metra, M. Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. Eur J Heart Fail. 18(4), 350\u2013352 (2016).","journal-title":"Eur J Heart Fail."},{"key":"63801_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ejhf.705","volume":"19","author":"HN Sabbah","year":"2017","unstructured":"Sabbah, H. N. Silent disease progression in clinically stable heart failure. Eur J Heart Fail. 19, 469\u2013478 (2017).","journal-title":"Eur J Heart Fail."},{"issue":"8","key":"63801_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18(8), 891\u2013975 (2016).","journal-title":"Eur J Heart Fail."},{"issue":"11","key":"63801_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 371(11), 993\u20131004 (2014).","journal-title":"N Engl J Med."},{"issue":"14","key":"63801_CR7","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/eurheartj\/ehs070","volume":"33","author":"JE Ho","year":"2012","unstructured":"Ho, J. E. et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 33(14), 1734\u20131741 (2012).","journal-title":"Eur Heart J."},{"key":"63801_CR8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam, C. S. P. et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 39, 1770\u20131780 (2018).","journal-title":"Eur Heart J."},{"key":"63801_CR9","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 33, 1750\u20131757 (2012).","journal-title":"Eur Heart J."},{"key":"63801_CR10","doi-asserted-by":"crossref","unstructured":"Silverio A, et al. Predictors of outcome in patients with de novo diagnosis of heart failure with reduced ejection fraction: Role of combined myocardial and lung Iodine-123 Meta-Iodobenzylguanidine imaging. J Nucl Cardiol. 2019 Feb 13 [Epub ahead of print]","DOI":"10.1007\/s12350-019-01637-8"},{"issue":"17","key":"63801_CR11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","volume":"102","author":"PS Jhund","year":"2016","unstructured":"Jhund, P. S. & McMurray, J. J. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan. Heart. 102(17), 1342\u20131347 (2016).","journal-title":"Heart."},{"key":"63801_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer, M. et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 131, 54\u201361 (2015).","journal-title":"Circulation."},{"issue":"9","key":"63801_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ejhf.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni, M. et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 18(9), 1193\u20131202 (2016).","journal-title":"Eur J Heart Fail."},{"issue":"10","key":"63801_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny, O. et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 18(10), 1228\u20131234 (2016).","journal-title":"Eur J Heart Fail."},{"issue":"2","key":"63801_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ehf2.12251","volume":"5","author":"H Norberg","year":"2018","unstructured":"Norberg, H., Bergdahl & Lindmark, K. Eligibility of sacubitril \u2013 valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail. 5(2), 337\u2013343 (2018).","journal-title":"ESC Heart Fail."},{"issue":"5","key":"63801_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/ehf2.12338","volume":"5","author":"R Rodil Fraile","year":"2018","unstructured":"Rodil Fraile, R., Malafarina, V. & Tiberio L\u00f3pez, G. Sacubitril \u2013 valsartan in heart failure and multimorbidity patients. ESC Heart Fail. 5(5), 956\u2013959 (2018).","journal-title":"ESC Heart Fail."},{"issue":"1","key":"63801_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","volume":"4","author":"MA Konstam","year":"2011","unstructured":"Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S. & Udelson, J. E. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 4(1), 98\u2013108 (2011).","journal-title":"JACC Cardiovasc Imaging."},{"issue":"8","key":"63801_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2459\/JCM.0000000000000679","volume":"19","author":"F D\u2019Auria","year":"2018","unstructured":"D\u2019Auria, F. et al. Predictors of left ventricular reverse remodeling in patients with chronic heart failure. J Cardiovasc Med. 19(8), 465\u2013469 (2018).","journal-title":"J Cardiovasc Med."},{"issue":"6","key":"63801_CR19","first-page":"108","volume":"7","author":"A Almufleh","year":"2017","unstructured":"Almufleh, A. et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril\/Valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 7(6), 108\u2013113 (2017).","journal-title":"Am J Cardiovasc Dis."},{"issue":"6","key":"63801_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jacbts.2017.08.001","volume":"2","author":"M Ishii","year":"2017","unstructured":"Ishii, M. et al. Cardioprotective Effects of LCZ696 (Sacubitril\/Valsartan) After Experimental Acute Myocardial Infarction. JACC Basic Transl Sci. 2(6), 655\u2013668 (2017).","journal-title":"JACC Basic Transl Sci."},{"key":"63801_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors, A. A. et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 17, 510\u2013517 (2015).","journal-title":"Eur J Heart Fail."},{"key":"63801_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ejhf.474","volume":"18","author":"Y Suematsu","year":"2016","unstructured":"Suematsu, Y. et al. LCZ696, an angiotensin receptor neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 18, 386\u2013393 (2016).","journal-title":"Eur J Heart Fail."},{"key":"63801_CR23","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1681\/ASN.V12102051","volume":"12","author":"MW Taal","year":"2001","unstructured":"Taal, M. W. et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 12, 2051\u20132059 (2001).","journal-title":"J Am Soc Nephrol."},{"key":"63801_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ejhf.462","volume":"18","author":"K Damman","year":"2016","unstructured":"Damman, K. et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 18, 328\u2013336 (2016).","journal-title":"Eur J Heart Fail."},{"key":"63801_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski, M. et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 42, 705\u2013708 (2003).","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"63801_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jacc.2016.05.013","volume":"68","author":"RJ Mentz","year":"2016","unstructured":"Mentz, R. J. & O\u2019Brien, E. C. Can 2 Pills a Day Keep Readmission Away?: Sacubitril\/Valsartan to Reduce 30-Day Heart Failure Readmissions. J Am Coll Cardiol. 68(3), 249\u2013251 (2016).","journal-title":"J Am Coll Cardiol."},{"key":"63801_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","volume":"55","author":"AS Levey","year":"2010","unstructured":"Levey, A. S. & Stevens, L. A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 55, 622\u2013627 (2010).","journal-title":"Am J Kidney Dis."},{"key":"63801_CR28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 33, 1787\u20131847 (2012).","journal-title":"Eur Heart J."},{"issue":"12","key":"63801_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi, M. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 18(12), 1301\u20131310 (2017).","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"63801_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/jcecho.jcecho_27_19","volume":"29","author":"MV Polito","year":"2019","unstructured":"Polito, M. V. et al. Analysis of regional right ventricular function by tissue Doppler imaging in patients with aortic stenosis. J Cardiovasc Echography. 29, 111\u2013118 (2019).","journal-title":"J Cardiovasc Echography."},{"key":"63801_CR31","doi-asserted-by":"crossref","unstructured":"Silverio A, et al. Predictors of outcome in patients with de novo diagnosis of heart failure with reduced ejection fraction: Role of combined myocardial and lung Iodine-123 Meta-Iodobenzylguanidine imaging. J Nucl Cardiol. Feb 13, (2019) [Epub ahead of print]","DOI":"10.1007\/s12350-019-01637-8"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63801-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:35:58Z","timestamp":1670319358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63801"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63801-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6665"}}